Description
Halozyme’s Breakthrough Moment: Could Its Game-Changing Subcutaneous Tech Disrupt Cancer Care Forever?
Halozyme Therapeutics’ third quarter 2025 results show a strong financial performance driven by its ENHANZE drug delivery technology and significant growth in royalty revenue. The company reported an impressive 52% increase year-over-year in royalty revenue, reaching $236 million. This growth, along with total revenue of $354 million, reflects a 22% increase year-over-year. The momentum is largely attributed to three key subcutaneous therapies: DARZALEX, VYVGART Hytrulo, and Phesgo, which continue to reshape healthcare delivery by allowing quicker and more convenient subcutaneous administration in various settings. The company’s EBITDA also increased by 35% compared to the prior year, reaching $248 million, underscoring the strength of its royalty-based business model. Halozyme’s ENHANZE technology reduces the need for lengthy infusions, thus offering patients greater convenience and reducing healthcare costs.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
